Vildagliptin added to sulfonylurea improves glycemic control without hypoglycemia and weight gain in Chinese patients with type 2 diabetes mellitus

Journal of Diabetes

Volumn 7, Issue 2, 2015, Pages 174-181

  Yang, Wenying ^a   Xing, Xiaoping ^b   Lv, Xiaofeng ^c   Li, Yiming ^e   Ma, Jianhua ^f   Yuan, Guoyue ^g   Sun, Feifei ^d   Wang, Wei ^d   Woloschak, Michael ^h   Lukashevich, Valentina ^h   Kozlovski, Plamen ^h   Kothny, Wolfgang ^h  

^a CHINA JAPAN FRIENDSHIP HOSPITAL   (China)

^b PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

^c CHINESE PLA GENERAL HOSPITAL   (China)

^d Beijing Baiao Pharmaceuticals Co Ltd   (China)

^e FUDAN UNIVERSITY   (China)

^f NANJING MEDICAL UNIVERSITY   (China)

^g AFFILIATED HOSPITAL OF JIANGSU UNIVERSITY   (China)

^h NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Chinese; Dipeptidyl peptidase 4; Glimepiride; Type 2 diabetes mellitus; Vildagliptin

Indexed keywords

GLIMEPIRIDE; GLUCOSE; HEMOGLOBIN A1C; INSULIN; METFORMIN PLUS PIOGLITAZONE; PIOGLITAZONE; VILDAGLIPTIN; ADAMANTANE; ANTIDIABETIC AGENT; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN; NITRILE; PYRROLIDINE DERIVATIVE; SULFONYLUREA DERIVATIVE;

ADD ON THERAPY; ADULT; AGED; ARTICLE; BODY WEIGHT; BRAIN INFARCTION; CELLULITIS; CHINESE; CONTROLLED STUDY; DIABETIC PATIENT; DOUBLE BLIND PROCEDURE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; INSULIN TREATMENT; MAINTENANCE DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECOMMENDED DRUG DOSE; TREATMENT OUTCOME; WEIGHT GAIN; ADOLESCENT; ANALOGS AND DERIVATIVES; ANALYSIS; BLOOD; CASE CONTROL STUDY; CHINA; CLINICAL TRIAL; COMPARATIVE STUDY; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; FOLLOW UP; GLYCEMIC INDEX; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; PROGNOSIS; RISK FACTOR; VERY ELDERLY; YOUNG ADULT;

ADAMANTANE; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BLOOD GLUCOSE; CASE-CONTROL STUDIES; CHINA; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; GLYCEMIC INDEX; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; NITRILES; PROGNOSIS; PYRROLIDINES; RISK FACTORS; SULFONYLUREA COMPOUNDS; WEIGHT GAIN; YOUNG ADULT;

EID: 84924217197     PISSN: 17530393     EISSN: 17530407     Source Type: Journal    
DOI: 10.1111/1753-0407.12169     Document Type: Article

References (28)

1. Yang W, Lu J, Weng J etal. China National Diabetes and Metabolic Disorders Study Group. Prevalence of diabetes among men and women in China. N Engl J Med. 2010; 362: 1090-1101.
2. International Diabetes Federation. IDF Diabetes Atlas, 6th edn. International Diabetes Federation, Brussels, 2013. Available from: http://www.idf.org/sites/default/files/EN_6E_Atlas_Full_0.pdf (accessed 14 June 2014).
3. Chinese Diabetes Society. China guideline for type 2 diabetes. Chin J Diabetes. 2012; 20 (Suppl.) S1-37.
4. Pan C, Xing X, Han P etal. Efficacy and tolerability of vildagliptin as add-on therapy to metformin in Chinese patients with type 2 diabetes mellitus. Diabetes Obes Metab. 2012; 14: 737-744.
5. An Y, Gao Y, Zhu Q etal. Features of insulin secretion and insulin resistance in Chinese newly-diagnosed type 2 diabetes. Chin J Endocrinol Metab. 2008; 24: 256-260.
6. Hanefeld M. Pioglitazone and sulfonylureas: Effectively treating type 2 diabetes. Int J Clin Pract Suppl. 2007; 61: 20-27.
7. Rodbard HW, Jellinger PS, Davidson JA etal. Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: An algorithm for glycemic control. Endocr Pract. 2009; 15: 540-559.
8. Turner RC, Cull CA, Frighi V, Holman RR. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: Progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA. 1999; 281: 2005-2012.
9. Ahrén B, Landin-Olsson M, Jansson PA, Svensson M, Holmes D, Schweizer A. Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes. J Clin Endocrinol Metab. 2004; 89: 2078-2084.
10. Balas B, Baig MR, Watson C etal. The dipeptidyl peptidase IV inhibitor vildagliptin suppresses endogenous glucose production and enhances islet function after single-dose administration in type 2 diabetic patients. J Clin Endocrinol Metab. 2007; 92: 1249-1255.
11. Mari A, Sallas WM, He YL etal. Vildagliptin, a dipeptidyl peptidase-IV inhibitor, improves model-assessed beta-cell function in patients with type 2 diabetes. J Clin Endocrinol Metab. 2005; 90: 4888-4894.
12. Villhauer EB, Brinkman JA, Naderi GB etal. 1-[[(3-Hydroxy-1-adamantyl)amino]acetyl]-2-cyano-(S)-pyrrolidine: A potent, selective, and orally bioavailable dipeptidyl peptidase IV inhibitor with antihyperglycemic properties. J Med Chem. 2003; 46: 2774-2789.
13. Garber AJ, Foley JE, Banerji MA etal. Effects of vildagliptin on glucose control in patients with type 2 diabetes inadequately controlled with a sulphonylurea. Diabetes Obes Metab. 2008; 10: 1047-1056.
14. Kikuchi M, Haneda M, Koya D etal. Efficacy and tolerability of vildagliptin as an add-on to glimepiride in Japanese patients with Type 2 diabetes mellitus. Diabetes Res Clin Pract. 2010; 89: 216-223.
15. Keating GM. Vildagliptin: A review of its use in type 2 diabetes mellitus. Drugs. 2014; 74: 587-610.
16. He YL. Clinical pharmacokinetics and pharmacodynamics of vildagliptin. Clin Pharmacokinet. 2012; 51: 147-162.
17. Pan C, Yang W, Barona JP etal. Comparison of vildagliptin and acarbose monotherapy in patients with Type 2 diabetes: A 24-week, double-blind, randomized trial. Diabet Med. 2008; 25: 435-441.
18. Harashima SI, Ogura M, Tanaka D etal. Sitagliptin add-on to low dosage sulphonylureas: Efficacy and safety of combination therapy on glycaemic control and insulin secretion capacity in type 2 diabetes. Int J Clin Pract. 2012; 66: 465-476.
19. Pratley RE, Kipnes MS, Fleck PR, Wilson C, Mekki Q, Alogliptin Study 007 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes inadequately controlled by glyburide monotherapy. Diabetes Obes Metab. 2009; 11: 167-176.
20. Karyekar C, Donovan M, Allen E, Fleming D, Ravichandran S, Chen R. Efficacy and safety of saxagliptin combination therapy in US patients with type 2 diabetes. Postgrad Med. 2011; 123: 63-70.
21. Lewin AJ, Arvay L, Liu D, Patel S, von Eynatten M, Woerle HJ. Efficacy and tolerability of linagliptin added to a sulfonylurea regimen in patients with inadequately controlled type 2 diabetes mellitus: An 18-week, multicenter, randomized, double-blind, placebo-controlled trial. Clin Ther. 2012; 34: 1909-1919.
22. de Heer J, Holst JJ. Sulfonylurea compounds uncouple the glucose dependence of the insulinotropic effect of glucagon-like peptide 1. Diabetes. 2007; 56: 438-443.
23. Jennings AM, Wilson RM, Ward JD. Symptomatic hypoglycemia in NIDDM patients treated with oral hypoglycemic agents. Diabetes Care. 1989; 12: 203-208.
24. Lund A, Knop FK. Worry vs knowledge about treatment-associated hypoglycaemia and weight gain in type 2 diabetic patients on metformin and/or sulphonylurea. Curr Med Res Opin. 2012; 28: 731-736.
25. Miller CD, Phillips LS, Ziemer DC, Gallina DL, Cook CB, El-Kebbi IM. Hypoglycemia in patients with type 2 diabetes mellitus. Arch Intern Med. 2001; 161: 1653-1659.
26. Chan SP, Ji LN, Nitiyanant W, Baik SH, Sheu WH. Hypoglycemic symptoms in patients with type 2 diabetes in Asia-Pacific-Real-life effectiveness and care patterns of diabetes management: The RECAP-DM study. Diabetes Res Clin Pract. 2010; 89: e30-32.
27. Hermansen K, Kipnes M, Luo E etal. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin. Diabetes Obes Metab. 2007; 9: 733-745.
28. Marfella R, Barbieri M, Grella R, Rizzo MR, Nicoletti GF, Paolisso G. Effects of vildagliptin twice daily vs sitagliptin once daily on 24-hour acute glucose fluctuations. J Diabetes Complications. 2010; 24: 79-83.